By Ben Glickman Oracle reported fiscal first-quarter growth in its cloud business slowed sequentially and compared to the year-ago quarter. Oracle's total.
Cantor Fitzgerald reaffirmed their overweight rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $6.00 price objective on the stock. Several other brokerages have also recently weighed in on HUMA. Benchmark reiterated a buy rating and issued a […]